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UltrasoundNanomedicines have provided fresh impetus in theﬁght against cancer due to their selectivity and power. However,
these agents are limited when delivered intravenously due to their rapid clearance from the bloodstream and poor
passage from the bloodstream into target tumours. Here we describe a novel stealthing strategy which addresses
both these limitations and thereby demonstrate that both the passive andmechanically-mediated tumour accumu-
lation of themodel nanomedicine adenovirus (Ad) can be substantially enhanced. In our strategy gold nanoparticles
were thoroughly modiﬁed with 2 kDa polyethyleneglycol (PEG) and then linked to Ad via a single reduction-
cleavable 5 kDa PEG. The resulting Ad–gold–PEG construct was compared to non-modiﬁed Ad or conventionally
stealthed Ad–poly[N-(2-hydroxypropyl)methacrylamide] (Ad–PHPMA). Notably, although Ad–gold–PEG was of
similar size and surface charge to Ad–PHPMA the increase in density, resulting from the inclusion of the gold nano-
particles, provided a substantial enhancement of ultrasound-mediated transport. In an in vitro tumour mimicking
phantom, the level and distance of Ad–gold–PEG transport was shown to be substantially greater than achieved
with Ad–PHPMA. In in vivo studies 0.1% of an unmodiﬁed Ad dose was shown to accumulate in tumours, whereas
over 12% of the injected dose was recovered from the tumours of mice treated with Ad–gold–PEG and ultrasound.
Ultimately, a signiﬁcant increase in anti-tumour efﬁcacy resulted from this strategy. This stealthing and density-
increasing technology could ultimately enhance clinical utility of intravenously delivered nanoscale medicines
including viruses, liposomes and antibodies.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Intravenous (IV) delivery of nanomedicines to tumours is sub-optimal
due to instability in the bloodstream and poor penetration from the
bloodstream and deep into tumours [1–3]. Interactionswith bloodstream
components have recently beenmore clearly deﬁned for a range of nano-
agents such as liposomes, nanoparticles and adenoviruses (Ad) [4–6].
Such studies have helped the development of chemical modiﬁcation
strategies which utilises polyethyleneglycol (PEG) or poly[N-(2-
hydroxypropyl)methacrylamide] (PHPMA) polymers to reduce
blood component binding and thereby improve circulation kinetics
[7–11]. However, such chemical ‘stealthing’ often provides insufﬁcient
protection to allow optimal activity of these nanomedicines, or modiﬁes
them to such an extent that their activity at the target site is compromised
[7,12]. Furthermore, although uptake of nano-sized agents into targete).
. This is an open access article undertumours beneﬁts from the enhanced permeability retention effect (EPR)
[13,14], such passive accumulation still only permits 1–2% of the injected
dose to accumulate. In response, device based approaches providing
physical/mechanical stimuli to actively drive nanomedicines from the
circulation deep into tumours have gained prominence, with application
of focussed ultrasound being recognised as a particularly attractive option
[15–17].
Here we describe an approach which provides enhancement of both
EPR assisted passive accumulation as well as device based mechanical
transport to tumours. Speciﬁcally, gold nanoparticles were sparselymod-
iﬁed with 5 kDa PEG and then heavily modiﬁed with 2 kDa PEG. The
resulting novel ‘dandelion’ construct was linked via a reduction labile di-
sulphide bond to the nanomedicine adenovirus, to give Ad–gold–PEG
(see Graphical abstract). Gold nanoparticles are an ideal nanomedicine
component due to their biocompatibility, low toxicity and amenability
to surface modiﬁcation.
Our dandelion-like structure provided a thick protective steric
shield of 2 kDa PEG similar to that achieved with multivalent PHPMA-
based polymers whilst still relying on one-point attachment of thethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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coating. The disulphide bond between the adenovirus and the gold-PEG
provided a mechanism for triggered de-stealthing and infection reactiva-
tionwithin reducing environments foundwithin tumours [18,19]. Attach-
ment of the dense steric shield via a minimal number of reducible 5 kDa
PEG linkswas designed to alloweffective de-shielding. Crucially, the addi-
tion of gold nanoparticles also substantially increased the density of the
Ad construct, thereby enhancing its response to focussed ultrasound in-
duced cavitation events. This strategy has the potential to broaden the
clinical utility of powerful therapeutic agents by enabling their successful
delivery following IV injection for cancer treatment.
2. Materials and methods
2.1. TNBS assay
A TNBS (2,4,6-Trinitrobenzenesulfonic acid) assay was used to
determine depletion of amine groups on gold andAdparticles in response
to addition of amine reactive PEG, PHPMAor gold–PEG [20]. In brief, stan-
dard curves of unmodiﬁed gold or Adwere treated identically to samples
and TNBS added before absorbance at 335 nm was measured.
2.2. Synthesis of Ad–gold–PEG
A sample of 1 × 1014 spherical amine-presenting 5 nm gold (~300
amine groups per gold particle; Nanopartz, USA) was ﬁrst conjugated
to 5 kDa carboxyl-PEG-thiol (Rapp Polymere, Germany) via EDC cross-
linker chemistry in 1 mL PBS (pH 4.5) at a molar ratio of 1 gold:10
5 kDa-PEG:50 EDC for 1 h at 25 °C. Amicon ultra-4 centrifugal ﬁlter
(GOLD-CF; Millipore, UK) with molecular weight cut-off of 100 kDa
was used to ﬁlter out excess 5 kDa-PEG. A TNBS assaywas used to deter-
mine loss of amine groups from the gold surface and thereby demon-
strate that on average 5 molecules of 5 kDa were attached per gold.
5 kDa-thiol-PEG–gold was later conjugated to 2 kDa methyl ether-
PEG-N-hydroxysuccinimide (Rapp Polymere, Germany) in 1 mL PBS
(pH 7.4) at a molar ratio of 1 × 5 kDa-PEG–gold:2000 2 kDa-PEG for
2 h at 25 °C. GOLD-CF was again used to ﬁlter out excess 2 k-PEG.
TNBS conﬁrmed the presence of an average of 257 molecules of 2 kDa
PEG per gold nanoparticle. Gold nanoparticles fully saturated with the
2 kDa-PEG-methyl ether and 5 kDa-PEG-thiol (gold–PEG)were reduced
in 1 M DTT buffer (pH 8) for 30 min to break any possible disulphide
bonds formed, and puriﬁcation was performed by GOLD-CF. Gold–PEG
was reacted with heterobifunctional reagent SPDP in 1 mL PBS
(pH 7.4) at a molar ratio of 1 gold–PEG:5000 SPDP for 1 h at 25 °C and
puriﬁed by GOLD-CF. The ﬁnal conjugation step was to react gold–
PEG–SPDP with adenovirus-type 5 ΔE1/E3 CMV-GFP (Ad; the Native
Antigen Company, UK) or Oncolytic Ad [21] in PBS (pH 7.4) at molar
ratio of 1 Ad:2000 gold–PEG–SPDP for 1 h at 25 °C. Final Ad–gold–PEG
particles were further puriﬁed by gel ﬁltration on a Sepharose CL-4B
column equilibrated with PBS (pH 7.4) and concentrated to 1 × 108
viral particles/μL in PBS with 10% glycerol for storage at 4 °C. The %
yield for Ad was 30% to 50%.
2.3. Characterization of Ad–gold–PEG
Dynamic light scattering and zeta potential data were obtained at
room temperature (RT) in PBS using Zetasizer Nano ZS instrument
(Malvern, UK). For TEM analysis, Ad samples were put on formvar-
coated 400 mesh copper grids (3.05 mm diameter; TAAB Laboratories
Equipment Ltd, UK) for 10 min; the grids were then stained with 2%
glutaraldehyde for 5 min, washed with 5 μL of ddH2O twice, stained
with 0.5% uranyl acetate for 1 min, and irradiated under the UV light
(254 nm) for 10min before being imaged under tomographic transmis-
sion electron microscope (model A-7650; Hitachi, Japan). The TEM
magniﬁcation was 70,000× at the accelerating voltage of 100 kV. The
processing of Ad for TEM leads to the loss of ﬁbre protein from thecapsid and so TEM gives a smaller capsid diameter compared to the
hydrodynamic diameter measured by DLS. ELISA experiments were
carried out as previously described [22]. In vitro experiments in which
IGROV-1 and SKOV-3 were infected with Ad or Ad–gold–PEG were car-
ried out in 96-well cell culture plates as previously described [4]. Some
slightmodiﬁcations included: for the IGROV-1 infection experiment, Ad
and Ad–gold–PEG were exposed to reducing buffer ranging from 0mM
to 10 mM β-mercaptoethanol (BME) for 20 min; 10 mM BME was
chosen as the highest level of reducing buffer because it has a reduction
potential of−260mV (pH 7) [23] whichmatches the reduction poten-
tials of many reported tumour micro-environments [19,24]. GFP
encoded by the Ad, and expressed in IGROV-1 or SKOV-3 cells upon
successful infection, was used to measure the efﬁcacy of infection for
each sample using a FACSCalibur ﬂow cytometer (Becton Dickinson,
UK). SDS-PAGE silver staining was performed as in [7]. In vitro ultra-
sound experiments were performed using IGROV cells grown in 1%
agar within and OptiCell pre-drilled to allow the formation of a ﬂow
channel, Ad sample and SonoVue were administered as a continuous
infusion through the channel during theultrasound exposure conditions
described in Supplementary Information Fig. S4.
2.4. Synthesis of Ad–PEG and Ad–PHPMA
The synthesis of Ad–PEG [25], PHPMA, and Ad–PHPMA [26] was
carried out as previously described. The characterization of PHPMA
showed that it contained 6.2 M% of thiazolidine-2-thione reactive
groups in side chains and had a molecular weight of 37,000 g/mol. In
brief for PEGylation; 25 μL of 40 mg/mL of 20 kDa NHS-PEG in DMSO
was added to 1mLofHEPES (pH7.4, 50mM)with 1× 1011 copies of Ad-
enovirus (=1Adper 300,000 PEG) for 2 h at RT. PEG of 20 kDawas used
to provide a mean size similar to that of Ad–gold–PEG and Ad–PHPMA
and for extended circulation in accordance with the ﬁndings of Doronin
et al. [8]. For PHPMA, 20mg/mL in HEPES (pH7.4, 50mM)was added to
1 × 1011 copies of Ad for 2 h at RT.
2.5. In vivo bio-distribution and circulation tests of modiﬁed Ad on mouse
models
CT26 or HepG2 cellsweremaintainedwithDMEMcell culturemedia
(10% FBS). Five-week-old BALB/c female mice were obtained from the
BMSU of the John Radcliffe Hospital (Oxford, UK). Eachmouse was sub-
cutaneously implanted with 5 × 105 CT26 or 5 × 106 HepG2 cancer cells
into the ﬂank. Once the tumours reached 100 to 150 mm3, mice were
dosed with 150 μL clodronate liposomes (ClodronateLiposomes.com,
Netherlands). 24 h later, mice were randomly divided into eight groups
of four mice, and each group was IV dosed with 1 × 1010 Ad, Ad–PEG,
Ad–PHPMA, or Ad–gold–PEG. 20 μL blood samples were taken 5, 15,
and 30 min after Ad injection and diluted to 200 μL in PBS. Quantitative
PCR (Q-PCR) was used to detect the presence of Ad DNA in extracted
DNA samples. tumour and liver samples were extracted following cull
at 35 min and DNA isolated and quantiﬁed as in [4]. In all cases the
quantity of adenovirus genomes in the blood, liver and tumour
accounted for 95–100% of the total injected dose. In ultrasound experi-
ments parameters and regimeswere as in [17]. The ultrasound frequen-
cy and range of pressures used in the present study are comparable to
those used in a number of recent studies seeking to enhance drug deliv-
ery to solid tumours other than in the brain [27]. Animal experimenta-
tion was performed according to UK Home Ofﬁce guidelines and the
UKCCCR Guidelines for Welfare of Animals in Experimental Neoplasia.
2.6. Statistical tests
Analyses used ANOVA followed by Newman–Keuls test for pairwise
comparison of sub-groups, *, **, and *** represent p-value b 0.05, 0.01,
and 0.001, respectively. Data is representative of at least two experiments.
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3.1. Formulation of gold–PEG and Ad–gold–PEG
Successful coating of Ad with reduction-cleavable gold–PEG was
demonstrated using dynamic light scattering (DLS), zeta (ζ) potential,
transmission electron microscopy (TEM), and SDS-PAGE silver staining,
(Fig. 1). Initial DLS analysis (Supplementary Fig. S1) showed gold–PEG
had a greater hydrodynamic diameter (15 nm) than gold (6.3 nm).
Unmodiﬁed Ad measured 117 nm, Ad–gold–PEG also comprised a single
mono-disperse population butmeasured 149 nmon average, a 32-nm in-
crease which corresponds to the combined size of addition of two gold–
PEG, demonstrating a good gold–PEG coating geometry. DLS analysis of
identically processed but non-linked Ad and gold–PEG (“Ad + gold–
PEG”) distinguished two peaks with means of 18 nm for gold–PEG and
114 nm for Ad (Fig. 1A). Treatment of Ad–gold–PEG with reducing
agent beta-mercaptoethanol (BME) cleaved the 5 kDa PEG which could
then be removed by ﬁltration to return the Ad to its original size. The ζ-
potential of gold became less positive (2.6 vs 0.2 Mv) after modiﬁcation,
as amine groups on the gold were removed by reaction with PEG. The
ζ-potential of Ad changed from−16.9 to−10.8 mV upon reaction with
gold–PEG (Supplementary Fig. S1).
Alteration to adenovirus capsid protein size after stealthing with
gold–PEG was characterized by separating the proteins by SDS-PAGE.
The resulting silver stain (Fig. 1B) indicated that neither Ad (lanes 1
and 2) nor Ad+ gold–PEG (lanes 5 and 6) showed a marked difference
in Ad protein band intensity in the presence or absence of reducing buff-
er. In contrast, analysis of Ad–gold–PEG (lanes 3 and 4) showed a
substantially different band migration pattern depending on the
presence or absence of reducingbuffer. Notably, in the absence of reduc-
ing agent (lane 4) there was relatively little migration of any Ad protein
into the gel, indicating that Ad protein was bound to gold–PEG and
unable to properly penetrate the polyacrylamide. However, uponAd + gold-PEG
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Fig. 1.Modiﬁcation of gold with PEG and Adwith gold–PEG. (A) Dynamic light scattering show
and Ad conjugated to gold–PEG (Ad–gold–PEG), or conjugated Ad–gold–PEG treated with beta
showing reduction-reversible retardedmigration of Adproteins following conjugation to gold–P
1 and 2= Ad, 3 and 4= Ad–gold–PEG, 5 and 6= Ad+ gold–PEG. Roman numerals denote po
(‘Au’), Ad, mixed Ad + gold–PEG or conjugated Ad–gold–PEG, images taken at the same magnexposure to reducing buffer (lane 3), Ad–gold–PEG showed equivalent
proteinmigration and intensity to that of Ad andnon-linked Ad+gold–
PEG, signifying the reduction-induced breakage of disulphide bonds be-
tween Ad and gold–PEG to un-stealth Ad to its original form. Analysis of
TEM images, as represented in Fig. 1C, showed an average of 60 gold–
PEG constructs per Ad capsid. Notably, because the 36 ﬁbre monomers
are lost from Ad during TEM processing any gold–PEG attached to
these regions cannot be visualised by this method. However, as SDS-
PAGE demonstrated that sufﬁcient gold–PEG was attached to each of
the 36 ﬁbre monomer proteins to prevent their migration it is reason-
able to calculate that at least 36 gold–PEG were attached to ﬁbre
proteins (but not detected by TEM). Adding the capsid (60) and ﬁbre
values (36) gives a total of approximately 96 gold–PEG per Ad. Notably,
TNBS analysis (Supplementary Fig. 2) showed the loss of 111 amine
groups from Ad upon reaction with gold–PEG. These analyses therefore
indicate that this dandelion stealthing procedure enables the over-
whelming majority of each of at least 96 gold–PEG to be linked to Ad
by just one 5 kDa PEG molecule.
3.2. Level of protection provided by Ad–gold–PEG stealthing
The biological consequences of the physicochemical changes which
were analysed in Fig. 1, were assayed using ELISA and infection of cancer
cell lines. ELISA using an anti-Ad antibody demonstrated a signiﬁcant
(p b 0.001) decrease in antibody binding to Ad–gold–PEG compared
to Ad and Ad + gold–PEG samples (Fig. 2A). Ad–gold–PEG showed
N10-fold lower (p b 0.001) binding to human blood cells after mixing
with whole human blood for 30 min at 37 °C, conﬁrming efﬁcient
stealthing was achieved (Supplementary Fig. S2B). This indicates good
protection of Ad from antibody and classical complement pathway
mediated sequestration by erythrocytes and leukocytes when gold–
PEG is used [4,29]. Studies in human ovarian carcinoma IGROV-1 cells
(which expresses high levels of the Coxsackievirus and AdenovirusSize (nm)
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Fig. 2.Gold–PEG for protection against anti-Ad antibody binding and cell infection. (A) Serial dilutions of sample weremade and an ELISA using anti-Ad antibodies performed. Ad= non-
modiﬁed Ad, Ad+ gold–PEG= control non-linked Ad and gold–PEG, Ad–gold–PEG= chemically conjugated Ad and gold–PEG. N= 5, SD shown. Analysis by one way ANOVA, *** = at
equivalent dilutions for all samples p b 0.001. (B) The utility of the reduction sensitive cleavage and un-stealthing mechanism was demonstrated by infecting with Ad or Ad–gold–PEG
which had been pre-incubated with a range of concentrations of the reducing agent BME and assaying expression of the GFP transgene encoded by the Ad, in terms of % of cells positive
for GFP. N = 4, SD shown.
13S. Mo et al. / Journal of Controlled Release 210 (2015) 10–18Receptors — CAR) showed substantially reduced infection activity for
Ad–gold–PEG, indicating that good stealthing of the Ad ﬁbre domain
whichbinds to CARhad been achieved (Fig. 2B). Furthermore, the utility
of the disulphide bond as a de-stealthing mechanismwas conﬁrmed as
42% of the infectivity of Ad–gold–PEG could be reactivated upon 20min
exposure to a reducing potential matching that of the extracellular
tumour milieu [19,23,24]. However, despite BME providing complete
removal of gold–PEG and thereby returning the Ad–gold–PEG to the
size and charge of non-modiﬁed Ad (DLS and zeta potential, Fig. 1)
full recovery of infection activity was not possible. This may be due to
the presence of thiol adducts which remain on the Ad surface post-
cleavage of the gold–PEG.
3.3. Passive accumulation of Ad–gold–PEG to tumours
Over a decade of research has produced two current, but never
directly compared, benchmark technologies for Ad stealthing; the use
of PEG [30] and the use of PHPMA [26]. Before testing the passive
tumour accumulation of novel Ad–gold–PEG constructs, conventionally
stealthed Ad–PEG and Ad–PHPMAwere prepared [25,31] to allow com-
parison to these accepted alternative strategies. Sizes and zeta poten-
tials were measured to ensure polymer coating was achieved. Notably,
as Ad–PEG, Ad–PHPMA and Ad–gold–PEG have very similar mean
diameters which measure in excess of the gaps in the sinusoidal endo-
thelium of both human and mouse liver [32], it may be expected that
they would experience the same level of passive removal on passage
through the liver. However, when compared by ELISA, Ad–gold–PEG
showed much more effective stealthing against the binding of anti-Ad
antibodies (Supplementary Fig. S3). In vivo studies were performed in
tumour-bearing murine models. After IV dosing of Ad, Ad–PEG, Ad–
PHPMA or Ad–gold–PEG, blood samples were taken and tumour and
liver samples extracted. Blood circulation proﬁles of Ad, Ad–PEG, Ad–
PHPMA and Ad–gold–PEG are shown in Fig. 3.
Ad, Ad–PEG and Ad–PHPMA circulation data was comparable to
previous published results [26,33]. The half-life of Ad–gold–PEG was
N30 min, meaning it outperformed all other groups, including Ad–
PHPMA. By 6 h post-injection negligible Ad and Ad–PEG, and approxi-
mately 10% of Ad–gold–PEG andAd–PHPMA remained in the circulation
and by24h less than 1% remained. Ad clearance inmicehas been shown
to result from extravasation through hepatic sinusoidal endothelia,
leading to infection of hepatocytes, and via capture by Kupffer cells
[34]. These PK data indicate that the superior stealthing achieved with
Ad–gold–PEG, as demonstrated in vitro by ELISA, impacted directly on
circulation and hepatic capture in vivo. Crucially, TNBS analysis showsthat this improved stealthing with Ad–gold–PEG was achieved with
modiﬁcation of just 111 capsid amine groups compared to 1332 with
Ad–PHPMA or 1007 with Ad–PEG (Supplementary Fig S2). In addition,
for the ﬁrst time in over a decade of development, we are able to
show a direct comparison of the blood circulation of Ad–PEG and Ad–
PHPMA and conﬁrm the relationship between the improved stealthing
with PHPMA (Supplementary Fig. S3) and the improved circulation
kinetics (Fig. 3A) compared to conventional PEGylation. Bio-distribution
of Ad, Ad–PEG, Ad–PHPMA, and Ad–gold–PEG is represented in Fig. 3B
(liver) and Fig. 3C (tumour). More than 90% of Ad and Ad–PEG was
captured by the liver. In contrast, liver capture of Ad–PHPMA and Ad–
gold–PEG decreased to 48% and 21%, respectively. Furthermore, 9-fold
more Ad–gold–PEG than Ad was recovered from the tumour. This is the
highest level of passive tumour accumulation that we have ever achieved
using this murine model. Integration of the areas under the curve (AUC)
for each sample in Fig. 3C and plotting of these data with their respective
total Ad accumulated per gramme of tumour, produced a strong correla-
tion (Fig. 3D, R2 = 0.6968), indicating that passive tumour accumulation
of adenovirus is dependent on its plasma AUC. This shows that the
enhanced chemical coating and protection of Ad–gold–PEG leads
to lower liver capture and extended circulation and ultimately
EPR-mediated accumulation. It is notable that these in vivo experiments
were performed in mice that had been pre-dosed with clodronate lipo-
somes. Such treatment is a clinically approvedmeans of depletingmacro-
phages andhas long been recognised as an effectiveway of enhancing the
circulation kinetics of unmodiﬁed Ad and polymer coated Ad inmice [26].
This also mimics current clinical practice whereby ‘pre-dosing’ with a
vector has been used to deplete macrophages and improve the pharma-
cokinetics of a subsequent ‘therapy dose’ of the same vector [35]. The
advantage of using clodronate to achieve the samemacrophage depletion
in preclinical tests is that QPCR measurement of the pharmacokinetics of
the therapy dose is not compromised by residual pre-dose.
3.4. Increased density of Ad–gold–PEG increases response to focussed
ultrasound in vitro
Experiments were performed to test if the presence of gold–PEG
could increase adenovirus response to focussed ultrasound and conse-
quently provide improved mechanically-mediated transport into
tumours. We and others have demonstrated that exposing tumours
to ultrasound provides a powerful stimulus for the movement of
nanomedicines from the bloodstream deep into tumours [16,17,36,
37]. Here we demonstrate that increasing the density of a nanomedicine
such as adenovirus by its attachment to gold–PEG increases its response
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Fig. 3. In vivo circulation assessment of injected Ad, Ad–PEG, Ad–PHPMA, and Ad–gold–PEG. 1 × 1010 copies of samplewere injected IV into BALB/c mice bearing CT26 tumours. (A) blood
sampling and quantiﬁcation byQPCR. n= 4, SD shown. Ad–gold–PEG, statistically different from all other groups p b 0.005. (B) Total % of the injected dose accumulated in livers. (C) Total
% of dose accumulated per gramme of tumourmass; (n=4), SD shown. Groups compared using ANOVA followed byNewman–Keuls test for pairwise comparison of sub-groups; * and ***
represents p-value b 0.05 and 0.001, respectively. (D) Relationship between Ad plasma circulation proﬁle and tumour accumulation. Each point represents one mouse treated with Ad
(black square), Ad–PEG (white/black triangle), Ad–PHPMA (purple circle), and Ad–gold–PEG (blue triangle). Area under curve calculated from circulation data at 30 min time point for
all mice, N = 8.
14 S. Mo et al. / Journal of Controlled Release 210 (2015) 10–18to ultrasound induced acoustic cavitation events (Fig. 4). There are no
previous reports where nanoparticle density has been modiﬁed to en-
hance response to focused ultrasound, although theory and work using
ballistics to deliver micro-particles transdermally [38] is in accordance
with our data.
Despite measuring similar diameters Ad, Ad–PHPMA and Ad–gold–
PEG showed dramatically different ultra-centrifugation separations,
with 99% of Ad–gold–PEG being recovered from the bottom of the
tube (Fig. 4A). This is in accordance with the theoretical increase in
density from Ad (1.37 g/mL) to Ad–gold–PEG (3.35 g/mL). When
applied through a ﬂow channel in a tissue mimicking material (TMM)
and exposed to ultrasound in the presence of ultrasound contrast agent
SonoVue (set-up in Supplementary Fig. S4) the amount of movement
into the TMM scaled with the amount of ultrasound induced inertial
cavitation events (as measured by passive cavitation detection [39])
(Fig. 4C–D). Substantially more Ad–gold–PEG, than Ad or Ad–PHPMA
moved into the TMM at all penetration depths tested. At a pressure of
1250 kPa 50 to 100-fold more Ad–gold–PEG was recovered at distances
of 4 and 6 mm from the ﬂow channel. These data demonstrate that
modulating nanomedicine density can alter response to ultrasound and
provide precise control over the depth of penetration, which has impor-
tant implications for the delivery of nanomedicines to tumours as well
as transdermally for vaccination. Exposure to BME and analysis of the
cells within the TMM for Ad encoded GFP gene expression conﬁrmedthat Ad–gold–PEG maintained infection capacity and had journeyed
further than the Ad, whilst also demonstrating that the ultrasound
parameters caused no cell damage (Supplementary Fig. S5). A signiﬁcant
increase (p b 0.001) in the depth of infection was observed (Supplemen-
tary Fig. S6). Notably, in contrast to Ad, infection was only evident with
Ad–gold–PEG when reducing agent BME was used, suggesting enhanced
selectivity for the tumour environment and therefore safety.
3.5. Passive accumulation and mechanical transport of Ad–gold–PEG
in vivo
Experiments were performed to test whether the enhanced passive
accumulation of Ad, achieved as a result of improved stealthing with
gold–PEG, could be combined with the increased ultrasound-mediated
mechanical transport, achieved as a result of the increased density
provided by stealthing with gold–PEG. As studies in Figs. 2 and 3 had
proven the superiority of Ad–gold–PEG vs Ad–PEG and Ad–PHPMA
these groups were no longer included.
Cancer cell killing oncolytic Ad was mixed with luciferase reporter
Ad as in [21] and then modiﬁed with gold–PEG or not and delivered
IV with the cavitation nuclei SonoVue to pre-clinical models (Fig. 5).
tumourswere exposed to ultrasound regimes as in [17] to create inertial
cavitation (see detection in Supplementary Fig. S7), or not, and bio-
distribution then assayed. This previous study had demonstrated these
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Fig. 4. Inﬂuence of increasing density on response to ultrasound. (A) Recovery of Ad, Ad–PHPMA and Ad–gold–PEG following ultracentrifugation through a caesium chloride density
gradient. (B) In vitro ultrasound set-up, Ad sample and the ultrasound contrast agent SonoVuewas applied via a ﬂowchannel through tissuemimickingmaterial (TMM) containing cancer
cells and exposed to ultrasound and the penetration of Ad into the TMMwasmeasured. (C–D) Inﬂuence of ultrasound exposure on the penetration of Ad samples into TMM. The left panel
shows a representative of the cavitation frequency spectra detected over the course of the 12 second ultrasound exposure as mapped using the passive cavitation detector. Broadband
acoustic emissions in D are indicative of the occurrence of inertial cavitation. In the right panel the number of Ad recovered at different distances from the vessel was quantiﬁed using
QPCR. N = 4, SD shown, ANOVA analysis performed.
15S. Mo et al. / Journal of Controlled Release 210 (2015) 10–18ultrasound parameters provided no cavitation and no enhancement of
virus transfer in the absence of SonoVue, and so this control was not
included here.
In accordance with Fig. 3A, substantially reduced liver capture (29.3%,
SD 2.14 vs 91.6% SD 8.36) was obtained with Ad–gold–PEG vs Ad,
resulting in 35-fold increase in the circulating dose at 30 min (Fig. 5A).
This provided a signiﬁcant (p b 0.005) increase in tumour load of Ad–
gold–PEG vs Ad, via passive accumulation (0.8% vs 0.1%). Notably, the
level Ad–gold–PEG dose in the bloodstream following ultrasound expo-
sure of the tumourwas substantially lower compared towhen ultrasoundwas not applied (58% vs 69%), suggesting ultrasound-mediated mechan-
ical transport of the Ad–gold–PEGout of the bloodstream. Indeed, the Ad–
gold–PEG dose in ultrasound treated tumours proved to be signiﬁcantly
(p b 0.001) and substantially (14-fold) enhanced compared to non-
ultrasound treated tumours (Fig. 5B). In total 12.2% (SD 0.97) of the
dose of Ad–gold–PEG was recovered from ultrasound treated tumours.
The previous highest level of ultrasound mediated enhanced uptake we
have achieved was 3-fold using Ad–PHPMA [16], and never before has
movement of dose into the tumour been so marked that it could be
evidenced by loss of dose from the bloodstream. The combined beneﬁt
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Fig. 5. Inﬂuence of ultrasound onmechanical transport to tumours. HepG2 tumour bearing CD-1nudemicewere injectedwith a single lowdose (1× 1010) of oncolytic AdorAd–gold–PEG
and tumours exposed to ultrasound or not and (A) bio-distribution and (B) tumour accumulationwasmeasured at 30min using QPCR, n= 4, SD shown, ANOVA analysis used. (C) In long
term studies tumours weremeasured using callipers until a size of 1000 mm3 was reached at which point mice were culled and (D) survival was plotted. Adenovirus genome content in
tumours wasmeasured at cull and related to day of cull. Brown circle= PBS, black square=Ad, black circle=Ad+ultrasound, blue triangle=Ad–gold–PEG, blue diamond=Ad–gold–
PEG + ultrasound, N = 8, SD shown, ANOVA analysis or log rank test in (D).
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ultrasound induced cavitation-mediated mechanical transport, (enhanc-
ing particle density), provided more than 100-fold more Ad–gold–PEG
within ultrasound treated tumours than Ad in non-ultrasound treated tu-
mours. When the adenovirus luciferase reporter gene expression was
measured at 24 h a 3-fold (p b 0.05) increase was observed in ultrasound
treated tumours (Supplementary Fig. S7C), as in previous studies [16].
Notably luciferase expression was lower for Ad–gold–PEG without ultra-
sound than for Ad+ ultrasound, despite equal levels of uptake. This may
be the result of Ad–gold–PEGwithout ultrasoundbeing deposited inwell-
perfused, non-reducing perivascular regions leading to inefﬁcient un-
coating and reactivation. Signiﬁcant retardation of tumour growth was
achieved in Ad–gold–PEG + ultrasound treated tumours (Fig. 5C) com-
pared to all other groups. This lead to increased survival of Ad–gold–
PEG + ultrasound treated mice compared to PBS, Ad, Ad + ultrasound
or Ad–gold–PEG treated mice by log rank test (P = 0.0001, 0.0017,
0.0263, 0.0023 respectively) (Fig. 5D). Analysis of Ad genome copies
present in tumours at cull (Supplementary Fig. S7D) revealed that Ad–
gold–PEG + ultrasound treated tumours contained N50, 20 and 100-
fold more Ad genomes than Ad, Ad + ultrasound or Ad–gold–PEG,
which was the worst performing group perhaps indicating poor access
to tumour regions in which effective un-coating of the gold–PEG and
reactivation of infection could take place. This emphasises the importance
of achieving improvements in mechanical transport into and throughout
the tumour as well as EPR assisted passive increases in the total amount
of tumour uptake, especially when ‘phenotypic’ low pH or reducingconditions are relied upon for drug release or activation. Physical mecha-
nisms such as ultrasoundmediated cavitation are ideally suited to achiev-
ing improvements in delivery, as they are non-invasive, safe and can be
monitored in real-time [40].
4. Discussion
Nanotechnologies are being developed to act as cancer drug delivery
systems, including polymer, protein and lipid based nanomedicines [41,
42]. Direct administration into tumours is inefﬁcient [43] and not
always feasible, and so nanomedicines that are amenable to IV delivery
are required. Regulation of size, shape, bloodstream stability and target
site activation will be crucial to the success of these agents [13,44–46].
We report a “dandelion” structure of multi-PEGylated gold nanoparti-
cles predominantly attached by a single reducible bond to the surface
of the nanomedicine adenovirus. The chemistry underpinning this
novel shielding methodology is in no way speciﬁc to adenovirus and
so this is a widely applicable method of providing nanomaterials with
improved protective steric shielding, without the requirement for activ-
ity compromising multivalent modiﬁcation of their surface. This pro-
vides advantages over existing stealthing methodologies and allows
improved protection against blood component binding. Furthermore,
the inclusion of a disulphide bond in the linkage between Ad and the
gold–PEG ensures that the activity of the nanomedicine can be recov-
ered in a tumour-triggered manner. In pre-clinical models, Ad–gold–
PEG had signiﬁcantly longer circulation time, lower liver capture, and
17S. Mo et al. / Journal of Controlled Release 210 (2015) 10–18increased tumour accumulation compared to Ad, Ad–PEG, and Ad–
PHPMA. The ability of this design to substantially enhance passive
tumour accumulation, makes it suitable for a future application in im-
proving the efﬁciency and scope of a range of therapeutic and diagnostic
nanotechnologies in the treatment of cancer including antibodies, pep-
tides and nucleotides. In addition, as this stealthing method also allows
the incorporation of nanoparticles, whether they are gold, carbon, iron
oxide, or quantum dots, it may allow the power of nanomedicines to
be combined with other new or clinically accepted nanoparticle based
imaging modalities.
The second novel ﬁnding we describe relates to the increase in
adenovirus particle density resulting from the linkage of gold–PEG
and the impact increased density has upon response to focused ultra-
sound induced cavitation. We show that such inertial cavitation events
can actively drive more Ad–gold–PEG to greater depths than similarly
sized but less dense Ad or Ad–PHPMA. Furthermore, by controlling the
ultrasound exposure parameters, the level of cavitation can be con-
trolled and the degree and depth of Ad–gold–PEG penetration tuned, a
process which is facilitated by the capacity to remotely map cavitation
events as they occur using passive acoustic mapping [40]. This level of
control and capacity for real-time feedback adds to the potential clinical
utility of this approach. Indeed, tackling the physical barrier of high
intratumoural pressure using a physical mechanism such as ultrasound
has several distinct advantages over alternative chemical approaches
such as vascular normalisation, which can even lead to the exclusion
of nanoparticles from tumours [47]. The precise mechanism by which
increasing the density of a nanotherapeutic enhances its cavitation-
mediated delivery warrants further computational and experimental
consideration. At the relatively low ultrasound frequency (0.5 MHz)
and acoustic pressure (b1.5 MPa) used acoustic streaming is very
weak and the nanotherapeutic is too small compared to the ultrasound
wavelength to experience a substantial radiation force. The mechanism
for delivery is therefore hypothesized to be microstreaming generated
by sustained inertial cavitation, whereby the collapsing microbubble
transfers momentum onto the surrounding liquid, which in turn entrains
any nanoparticles suspended within it. The denser the nanoparticle, the
more difﬁcult it is for it to reach its terminal velocity, but the farther it
will travel once that terminal velocity is reached due to having greater
momentum than the surrounding liquid. We therefore hypothesize that
a denser nanotherapeutic acquires momentum from the surrounding
microstreaming ﬂuid more effectively under conditions of sustained
inertial cavitation.
5. Conclusions
We demonstrate that the passive accumulation and mechanical
transport of a model nanomedicine adenovirus into tumours can be
improved by the attachment of gold–PEGnanoparticles and the applica-
tion of ultrasound to provide substantial enhancement to anti-tumour
efﬁcacy. This platform nanotechnology and these beneﬁts could be
applied to a wide range of nanomedicines.
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